Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (?Aptose? or the ?Company?) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Jotin Marango, M.D., Ph.D., Senior Vice President and Chief Business Officer, will participate at the 5th International Conference on Acute Myeloid Leukemia ?Molecular and Translational? Advances in Biology and Treatment, and present preclinical data for CG-806, its oral, first-in-class pan-FLT3/pan-BTK inhibitor, in a poster presentation on October 24th, 2019 in Estoril, Portugal.